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Abstract
Background: The effects of the olive oil-rich Mediterranean diet on breast cancer risk might be underestimated when HER2
(ERBB2) oncogene-positive and HER2-negative breast carcinomas are considered together. We here investigated the anti-HER2
effects of phenolic fractions directly extracted from Extra Virgin Olive Oil (EVOO) in cultured human breast cancer cell lines.
Methods: Solid phase extraction followed by semi-preparative high-performance liquid chromatography (HPLC) was used to
isolate phenolic fractions from commercial EVOO. Analytical capillary electrophoresis coupled to mass spectrometry was
performed to check for the composition and to confirm the identity of the isolated fractions. EVOO polyphenolic fractions were
tested on their tumoricidal ability against HER2-negative and HER2-positive breast cancer in vitro models using MTT, crystal
violet staining, and Cell Death ELISA assays. The effects of EVOO polyphenolic fractions on the expression and activation status
of HER2 oncoprotein were evaluated using HER2-specific ELISAs and immunoblotting procedures, respectively.
Results: Among the fractions mainly containing the single phenols hydroxytyrosol and tyrosol, the polyphenol acid elenolic acid,
the lignans (+)-pinoresinol and 1-(+)-acetoxypinoresinol, and the secoiridoids deacetoxy oleuropein aglycone, ligstroside aglycone,
and oleuropein aglycone, all the major EVOO polyphenols (i.e. secoiridoids and lignans) were found to induce strong tumoricidal
effects within a micromolar range by selectively triggering high levels of apoptotic cell death in HER2-overexpressors. Small
interfering RNA-induced depletion of HER2 protein and lapatinib-induced blockade of HER2 tyrosine kinase activity both
significantly prevented EVOO polyphenols-induced cytotoxicity. EVOO polyphenols drastically depleted HER2 protein and
reduced HER2 tyrosine autophosphorylation in a dose- and time-dependent manner. EVOO polyphenols-induced HER2
downregulation occurred regardless the molecular mechanism contributing to HER2 overexpression (i.e. naturally by gene
amplification and ectopically driven by a viral promoter). Pre-treatment with the proteasome inhibitor MG132 prevented EVOO
polyphenols-induced HER2 depletion.
Conclusion: The ability of EVOO-derived polyphenols to inhibit HER2 activity by promoting the proteasomal degradation of
the HER2 protein itself, together with the fact that humans have safely been ingesting secoiridoids and lignans as long as they
have been consuming olives and OO, support the notion that the stereochemistry of these phytochemicals might provide an
excellent and safe platform for the design of new HER2-targeting agents.
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Background
Case-control, cohort, and prospective epidemiological
studies have generated conflicting results regarding a pro-
tective effect of an olive oil (OO)-rich Mediterranean diet
against several malignancies, especially breast cancer [1-
5]. It has been assumed that, if protective agents (e.g.
monounsaturated fatty acids such as oleic acid and/or
antioxidants from olive oil and raw vegetables) are largely
present in the diet of a population with a low risk of
acquiring solid tumors (i.e.  dietary patterns found in
olive-growing areas of the Mediterranean basin), these
diet-based anti-cancer mechanisms should influence the
occurrence of all or most types of cancer. Sant et al. [6], by
analyzing the data of the ORDET prospective study on
hormones, diet and breast cancer [7], have recently sug-
gested that the effects of the Mediterranean diet on breast
cancer risk might be underestimated when HER2 (ERBB2)
oncogene-positive and HER2-negative breast carcinomas
are considered together. The Type I receptor tyrosine
kinase (RTKs) HER2 regulates biological functions as
diverse as cellular proliferation, transformation, differen-
tiation, motility and apoptosis. HER2 is therefore one of
the most commonly analyzed proto-oncogenes in human
cancer studies, as it plays a pivotal role in oncogenic trans-
formation, tumorigenesis, and metastasis [8-12]. HER2
gene is amplified and/or overexpressed in ~20% to 30%
of invasive breast carcinomas and is associated with unfa-
vorable prognosis, shorter relapse time, and decreased
overall survival [8-12].
Although one observational study is not sufficient and
consistency of findings across multiple cohort and case-
control studies is paramount to definitely establish
whether the protective effect of a diet rich in raw vegeta-
bles and OO is largely restricted to HER2-positive breast
carcinomas, when considering experimental and epidemi-
ological evidence together it is reasonable to suggest that
dietary factors influencing the occurrence of HER2-posi-
tive breast carcinomas may differ from those influencing
the occurrence of HER2-negative cancers [6]. Moreover,
an OO, salad and vegetable-rich dietary pattern might
specifically exert a protective effect against HER2-positive
breast cancer because the (anti-cancer) mechanism of
action of some of its components largely depends on their
ability to suppress HER2 expression. We previously dem-
onstrated that an experimental diet with a high content in
Extra Virgin OO (i.e. the juice of the olive obtained solely
by pressing and consumed without any further refining
process) acted as a negative modulator on the promotion
stage of dimethylbenz(a)anthracene (DMBA)-induced
mammary tumors in rats by conferring to the tumors a
more benign clinical behavior and lower histopathologi-
cal malignancy [13]. Mechanistically, both in vivo and in
vitro studies revealed that oleic acid (OA; 18:1n-9) – the
main EVOO's monounsaturated fatty acid (MUFA) – tran-
scriptionally suppressed the expression of HER2 gene [14-
19]. We recently described that the polyphenol oleuro-
pein aglycone, a non-glyceridic constituent of EVOO, was
capable to reverse breast cancer acquired autoresistance to
the anti-HER2 monoclonal antibody trastuzumab (Her-
ceptin™) [20]. However, the HER2-related anti-breast can-
cer activities of polyphenolic compounds present in the
soluble fraction of EVOO other than oleuropein aglycone,
which have been suggested to contribute the oxidative sta-
bility of EVOO, and as such are often associated with the
health benefits of EVOO [21-24], remained to be fully
evaluated.
We here designed a systematic approach to investigate the
effects of EVOO-derived polyphenol compounds on the
expression and oncogenic activity of the HER2 tyrosine
kinase in human breast cancer-derived cell lines. EVOO is
unique among other vegetable oils because of its high
level of phenolic compounds [25-29]. These levels are
possible because it is obtained from the olive fruit (Olea
Europea L.) solely by mechanical means, without further
treatment other than washing, filtration, decantation, or
centrifugation (Figure 1). To evaluate a potential thera-
peutic role for EVOO polyphenols it is important to either
synthesize or isolate individual compounds. Synthesis is
currently not practical and, therefore, isolation proce-
dures must be used. First, solid phase extraction followed
by semi-preparative high-performance liquid chromatog-
raphy (HPLC) was used to isolate phenolic fractions from
commercial EVOO. Second, analytical capillary electro-
phoresis coupled to mass spectrometry (CE-MS) was per-
formed to check for the composition of the isolated
phenolic fractions and to confirm their identity. Third, the
effects of EVOO phenolic fractions on breast cancer cell
viability, proliferation and apoptosis were assessed using
MTT, crystal violet staining, and Cell Death ELISA assays,
respectively. Fourth, the effects of EVOO phenolic frac-
tions on the expression levels and the activation status of
HER2 oncoprotein were evaluated using HER2-specific
ELISAs and immunoblotting procedures, respectively.
Fifth, we preliminary addressed the molecular mecha-
nisms underlying the anti-HER2 effects of EVOO-derived
polyphenols.
We report for the first time that all the fractions containing
the major EVOO polyphenols (i.e. the secoiridoids deace-
toxy oleuropein aglycone, ligstroside aglycone, oleuro-
pein aglycone and the lignans [+]-pinoresinol and 1-[+]-
acetoxypinoresinol) can efficiently inhibit HER2 protein
kinase activity by depleting the HER2 protein kinase itself.
We suggest that the stereochemistry of these phytochemi-
cals might provide an excellent and safe platform for the
design of new HER2-targeted anti-breast cancer drugs.BMC Cancer 2008, 8:377 http://www.biomedcentral.com/1471-2407/8/377
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Methods
Apparatus
Semi-preparative HPLC was performed with a HP 1100
series (Agilent Technologies, Palo Alto, CA, USA),
equipped with a binary pump delivery system, a degasser,
an autosampler, a diode array UV-VIS detector (DAD).
The semi-preparative HPLC column used was a Phenom-
enex Luna (C18) column, 10 μm i.d., 25 cm × 10 mm and
the flow rate was 3 mL/min.
Capillary electrophoresis (CE) were performed using a in
a P/ACE™ System MDQ (Beckman Instruments, Fullerton,
CA, USA). Fused-silica capillaries of 85 cm in length and
50  μm inner diameter (360 μm outer diameter) were
used. CE apparatus was coupled to the mass spectrometer
detector by an orthogonal electrospray interface (ESI).
Mass spectrometer was a microTOF™ (Bruker Daltonik,
Bremen, Germany), an orthogonal-accelerated TOF mass
spectrometer (oaTOF-MS). Good sensitivity at a reasona-
ble resolution was obtained (5,000–10,000 at 250 m/z).
The trigger time was set to 50 μs, corresponding to a mass
range of 50–800 m/z. Spectra were acquired by summariz-
ing 30,000 single spectra, defining the time resolution to
1.5 s.
Reagents, stock solutions and reference compounds
Methanol and n-hexane HPLC-grade were from Merck
(Darmstadt, Germany). Distilled water with a conductiv-
ity of 18.2 MΩ was deionized by using a Milli-Q system
(Millipore, Bedford, MA, USA). Oleuropein glycoside was
Chromatogram of EVOO sample using semi-preparative HPLC Figure 1
Chromatogram of EVOO sample using semi-preparative HPLC. Solid-liquid extraction of polyphenols from EVOO 
(i.e. the juice of the olive obtained solely by pressing and consumed without any further refining process) was performed as 
described in "Materials and methods". Detection was performed at 280 nm. Isolated fractions and main peak identified in each 
fraction: 1, hydroxytyrosol; 2, tyrosol; 3, elenolic acid (was detected at 240 nm); 4, DAOA; 5, (+)-pinoresinol;6, 1-(+)-acetox-
ypinoresinol;7, oleuropein aglycone;8, ligstroside aglycone.BMC Cancer 2008, 8:377 http://www.biomedcentral.com/1471-2407/8/377
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obtained from Extrasynthèse (Genay, France). Trastuzu-
mab (Herceptin™) – kindly provided by Hospital Univer-
sitari de Girona Dr. Josep Trueta Pharmacy (Girona,
Spain) – was solubilized in bacteriostatic water for injec-
tion containing 1.1% benzyl alcohol (stock solution at 21
mg/ml), stored at 4°C and used within one month. Lap-
atinib (GW572016; Tykerb®) was gently provided by Glax-
oSmithKline (GSK), Corporate Environment, Health &
Safety (Brentford, Middlesex TW8 9GS UK). MG-132 was
purchased from Calbiochem (Calbiochem, San Diego,
CA, USA). N-acetylcysteine and Trolox were purchased
from Sigma-Aldrich (St. Louis, MO, USA). Lapatinib, MG-
132, and Trolox were dissolved in DMSO and stored in
the dark as stock solutions (10 mM) at -20°C until utili-
zation. NAC was dissolved in Phosphate Buffered Saline
(PBS) immediately before utilization. For experimental
use, trastuzumab, lapatinib, MG-132, NAC and Trolox
were prepared freshly from stock solutions and diluted
with growth medium. Control cells were cultured in
medium containing the same concentration (v/v) of vehi-
cles as the experimental cultures with treatments. The
vehicle solutions had no noticeable influence on the pro-
liferation of experimental cells.
Sample, extraction, isolation and analysis of polyphenol 
fractions from EVOO
A 50/50 mixture of two commercial EVOO samples (i.e.
Picual and Arbequina Spanish varieties) was used for this
study. We have used solid phase extraction (SPE) with
Diol-cartridges followed by semi-preparative reverse
phase-HPLC to isolate different fractions of phenolic
compounds from the EVOO. Capillary electrophoresis-
electrospray ionization-mass spectrometry (CE-ESI-MS)
was then employed to establish the composition of the
isolated fractions because the principles of separation are
completely different to semi-preparative chromatographic
employed to isolate the EVOO fractions [30-37]. The
identification of the phenolic compounds was obtained
from the accurate mass and the isotopic pattern of the
peaks applying ESI-TOF-MS analyzer. The actual composi-
tion of the isolated phenolic fractions, including experi-
mental  m/z, the average molecular weight and, when
available, the names of the phenolic compounds, is
detailed in Table 1. The fractions 1, 2, 3 and 8 mainly
included a single compound (i.e. hydroxytyrosol, tyrosol,
elenolic acid and ligstroside aglycone, respectively), while
the fractions 4, 5, 6 and 7 included a mixture of several
polyphenolic compounds (Figure 2). In order to simplify
both the results and the discussion sections, the total com-
position of fractions 4, 5, 6 and 7 was expressed as the
main compound contributing to each fraction (i.e. deace-
toxyoleuropein aglycone – DAOA-, pinoresinol, acetox-
ypynoresinol and oleuropein aglycone, respectively).
Retention times, absorption maxima, the MS data using
accurate mass and analytical parameter of the HPLC-MS
method are detailed in Tables 1 and 2 (Additional file 1).
Table 1: Composition of the isolated EVOO phenolic fractions using CE-ESI-MS
Isolated fraction Phenol composition
m/z experimental Name
1 153.0557 Hydroxytyrosol
2 137.0609 Tyrosol
3 241.0721 Elenolic acid
4 319.1171 Deacetoxy oleuropein aglycone (DAOA)
393.1186 Unknown 1
185.1176 Unknown 2
297.1510 Unknown 3
191.0563 Unknown 4
5 357.1135 Pinoresinol
303.1225 Deacetoxy ligstroside aglycone
361.1308 Ligstroside aglycone
6 415.1393 Acetoxypinoresinol
303.1225 Deacetoxy ligstroside aglycone
361.1285 Ligstroside aglycone
377.1266 Oleuropein aglycone
257.0669 Unknown 5
73 7 7 .  1 2 4 9 Oleuropein aglycone
361.1286 Ligstroside aglycone
333. 1456 Unknown 6
287.2239 Unknown 7
407.1363 Unknown 8
239.0552 Unknown 9
8 361.1308 Ligstroside aglyconeBMC Cancer 2008, 8:377 http://www.biomedcentral.com/1471-2407/8/377
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Cell lines and culture conditions
MCF-7 and SKBR3 breast cancer cells were obtained from
the American Type Culture Collection (ATCC) and they
where routinely grown in Improved MEM (IMEM; Bio-
source International) supplemented with 10% fetal
bovine serum (FBS) and 2 mM L-Glutamine. Cells were
maintained at 37°C in a humidified atmosphere of 95%
air and 5% CO2. Cells were screened periodically for Myc-
oplasma  contamination. EVOO polyphenols were pre-
pared freshly from stock solutions and diluted with
growth medium. Control cells were cultured in medium
containing the same concentration (v/v) as the experimen-
tal cultures with treatments. The vehicle solutions had no
noticeable influence on the proliferation of experimental
cells.
Construction of pBABE/HER2 retroviruses and retroviral 
infection of MCF-7 cells
A full-length human HER2 cDNA construct in the pCMV-
SPORT6 plasmid was purchased from RZPD (Berlin, Ger-
many). The insert was excised from pCMV-SPORT6 using
EcoRV and NotI sites and blunt end ligated into the
pBABE-puro retroviral vector (Addgene) at the EcoRI site.
Retroviruses were generated by co-transfection of 293T-
Effects of EVOO phenolics on breast cancer cell viability Figure 2
Effects of EVOO phenolics on breast cancer cell viability. Figure shows the chromatographic profile of an EVOO sam-
ple and the extracted ion of the main phenolics of each fraction. Detection of EVOO phenolics was performed at 280 nm (only 
in the analysis of elenolic acid – peak number 3 – the detection was performed at 240 nm). The metabolic status of EVOO 
polyphenols-treated SKBR3 cells was evaluated using a MTT-based cell viability assay and constructing dose-response curves as 
described in "Materials and methods". Concentrations producing the IC50 value (the concentration of each compound or main 
compound of the each fraction needed to reduce cell viability by 50% relative to untreated control cells) were calculated by 
interpolation. Values are means (in μM) and 95% confidence intervals (95% CI) of three independent experiments made in trip-
licate.BMC Cancer 2008, 8:377 http://www.biomedcentral.com/1471-2407/8/377
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derived phoenix cells with the retroviral constructs
(pBABE, pBABE-HER2) and the packaging vector pCL-Eco
by using FuGene transfection reagent (Roche Diagnostics,
Barcelona, Spain) and 5 μg of each plasmid per 0.5 × 106
cells. 293T cells were cultured at 5% CO2, 37°C in DMEM
containing 10% (v/v) heat-inactivated FBS. After 48 h,
medium conditioned by transfected 293T cells was fil-
tered and immediately added to MCF-7 cells in the pres-
ence of 4 μg/ml polybrene (Sigma-Chemicals, St. Louis,
MO, USA). At 48 h following infection, MCF-7/pBABE
and MCF-7/HER2 cells were selected by using 2.5 μg/ml
puromycin for 72 h. Expression of virally encoded HER2
protein was confirmed by HER2-specific ELISA analyses
(see below).
Metabolic status assessment (MTT-based cell viability 
assays)
Breast cancer cell viability was determined using a stand-
ard colorimetric MTT (3-4, 5-dimethylthiazol-2-yl-2, 5-
diphenyl-tetrazolium bromide) reduction assay. Cells in
exponential growth were harvested by trypsinization and
seeded at a concentration of ~2.5 × 103 cells/200 μl/well
into 96-well plates, and allowed an overnight period for
attachment. Then the medium was removed and fresh
medium along with various concentrations of EVOO phe-
nolic fractions, trastuzumab, lapatinib, NAC, Trolox, and/
or MG-132 were (concurrently or sequentially) added to
cultures as specified. Control cells without agents were
cultured in parallel using the same conditions with com-
parable media changes. Compounds were not renewed
during the entire period of cell exposure. Following treat-
ment (5 days), the medium was removed and replaced by
fresh drug-free medium (100 μl/well), and MTT (5 mg/ml
in PBS) was added to each well at a 1/10 volume. After
incubation for 2–3 hr at 37°C, the supernatants were care-
fully aspirated, 100 μl of DMSO were added to each well,
and the plates agitated to dissolve the crystal product.
Optical Density (OD) was measured at 570 nm using a
multi-well plate reader (Model Anthos Labtec 2010 1.7
reader). The cell viability effects from exposure of cells to
each polyphenol fraction alone were analyzed as percent-
ages of the control cell absorbances, which were obtained
from control wells treated with appropriate concentra-
tions of the compounds vehicles that were processed
simultaneously. For each treatment, cell viability was eval-
uated as a percentage using the following equation:
>(OD570 of treated sample/OD570 of untreated sample) × 
100.
Breast cancer cell sensitivity to agents was expressed in
terms of the concentration of drug required to decrease by
50% cell viability (IC50 value). Since the percentage of
control absorbance was considered to be the surviving
fraction of cells, the IC50 values were defined as the con-
centration of agents that produced 50% reduction in con-
trol absorbance (by interpolation), respectively.
Cell proliferation (crystal violet staining)
The ability of EVOO polyphenol compounds to affect
breast cancer cells proliferation was determined using a
crystal violet cell staining assay. Crystal violet is an intense
stain binding to the cell nuclei and gives an OD595 reading
that is proportional to cell number. Cells were plated and
treated as described above (MTT assays). Following treat-
ments, cells were fixed by replacing the growth medium
with 100 μl/well of 4% formaldehyde in PBS (20 minutes,
RT). Formaldehyde solution was removed and cells were
washed twice with 200 μl/well Wash Buffer (0.1% Triton
X-100 in PBS) and 2 times with 200 μl/well 1 × PBS. 100
μl of crystal violet solution was added to each well and
incubated 30 minutes at RT. Cell were then washed 3
times with 200 μl/well 1 × PBS, 100 μl of 1% SDS solution
was added to each well, and plates were incubated on a
shaker for 1 hour at RT. Optical Density (OD) was meas-
ured at 595 nm using a multi-well plate reader (Model
Anthos Labtec 2010 1.7 reader), and the cell proliferation
effects from exposure of cells to each fraction were ana-
lyzed as percentages of the control cell absorbances,
which were obtained from control wells treated with
appropriate concentrations of the compounds vehicles
that were processed simultaneously. For each treatment,
cell proliferation was evaluated as a percentage using the
following equation:
(OD595 of treated sample/OD595 of untreated sample) × 
100.
Apoptosis assays
The ability of EVOO-derived phenolic compounds to
induce apoptosis was assessed using the Cell Death Detec-
tion ELISAPLUS kit obtained from Roche Diagnostics (Bar-
celona, Spain). Briefly, cells (5 to 10 × 103/well) were
grown in 96-well plates and treated, in duplicates, for 72
h with the indicated doses of EVOO polyphenols, as spec-
ified. After treatment, the 96-well plates were centrifuged
(200 × g) for 10 min. The supernatant was discharged,
lysis buffer was added, and samples were incubated at
room temperature (RT) for 30 min following the manu-
facturer's instructions. Anti-histone biotin and anti-DNA
peroxidase antibodies were added to each well and incu-
bated at RT for 2 h. After three washes, the peroxidase sub-
strate was added to each well, and the plates were read at
405 nm at multiple time intervals. The enrichment of his-
tone-DNA fragments in treated cells was expressed as fold
increase in absorbance as compared with control (vehicle-
treated) cells.BMC Cancer 2008, 8:377 http://www.biomedcentral.com/1471-2407/8/377
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Transient transfection of small interference RNAs
The small interfering RNA sequences used for targeted
silencing of human HER2 were supplied by Santa Cruz
Biotech (Santa Cruz, CA, USA) as double-stranded small
interference RNA [Neu siRNA (h) sc-29405]. siRNA A (sc-
37007), which consists of a scrambled sequence that will
not lead to the specific degradation of any known cellular
mRNA, was employed as negative control for experiments
using HER2-targeted siRNA transfection. Transfections
were performed as described in Santa Cruz technical bul-
letin. Briefly, cells at a confluence of 60 to 80% were trans-
fected with the selected small interference RNAs using
Santa Cruz Biotechnology's siRNA Transfection Reagent
(sc-29528) and siRNA Transfection Medium (sc-36868)
following the manufacturer's instructions.
HER2-specific Enzyme-Linked Immunosorbent Assay
Determination of HER2 protein content was performed
with a commercially available quantitative ELISA (Onco-
gene Science, Bayer Diagnostics) according to the manu-
facturer's protocol. To assess the effects of EVOO phenols,
HER2 siRNA, NAC, and Trolox on HER2 protein concen-
trations, breast cancer cells, after a 24 h starvation period
in media without serum, were incubated with graded con-
centrations of EVOO phenolics, HER2 siRNA, siRNA A,
NAC or Trolox as specified. After treatment, cells were
washed twice with cold-PBS and then lysed in buffer (20
mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate,
1 mM β-glycerolphosphate, 1 mM Na3VO4, 1 μg/ml leu-
peptin, 1 mM phenylmethylsulfonylfluoride) for 30 min-
utes on ice. The lysates were cleared by centrifugation in
an Eppendorff tube (15 minutes at 14,000 × g, 4°C). Pro-
tein content was determined against a standardized con-
trol using the Pierce Protein Assay Kit (Rockford, IL, USA).
1:50, 1:500; 1: 5,000 and 1:10,000 dilutions of total cell
lysates from EVOO phenols-treated, HER2 siRNA-trans-
fected and control untreated cells were used to quantitate
HER2 protein expression in cell cultures. A standard curve
was generated by using standard solutions as per manu-
facturer's instructions. The concentrations of HER2 in test
samples (in nanograms of HER2 per milligram of total
protein) were determined by interpolation of the sample
absorbances from the standard curve. Each experiment
was performed in duplicate wells.
Activation status of HER2
Testing for the phosphorylation (activation) status of
HER2 was performed by immunoblotting procedures
using the monoclonal c-erbB2/HER2 (phosphor-specific)
antibody Ab-18 (NeoMarkers, Fremont, CA, USA). Briefly,
EVOO polyphenols-treated and untreated control cells
were washed twice with cold PBS and then lysed as
described above. Equal amounts of protein (i.e. 50 μg)
were resuspended in 5× Laemli sample buffer (10 min at
70°C), resolved by electrophoresis on 3–8% NuPAGE
Tris-Acetate and transferred onto nitrocellulose mem-
branes. Non-specific binding on the nitrocellulose filter
paper was minimized by blocking for 1 h at RT with TBS-
T buffer [25 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.05%
Tween 20] containing 5% (w/v) nonfat dry milk. The
treated filters were washed in TBS-T and then incubated
with the phospho-c-erbB2/HER2 (clone PN2A) antibody
in 5% w/v BSA, 1 × TBS-T buffer, 0.1% Tween-20 at 4°C
with gentle shaking, overnight. The membranes were
washed in TBS-T, horseradish peroxidase-conjugated sec-
ondary anti-mouse IgG in TBS-T was added for 1 h, and
immunoreactive bands were detected by chemiluminis-
cence reagent (Pierce, Rockford, IL). Blots were re-probed
with an antibody for β-actin to control for protein loading
and transfer (data not shown). Densitometric values of
proteins bands were quantified using the Scion Image
software (Scion Corporation, Frederick, MD, USA).
Statistics
Two-group comparisons were performed by the Student t
test for paired and unpaired values. Comparisons of
means of ≥ 3 groups were performed by ANOVA, and the
existence of individual differences, in case of significant F
values at ANOVA, tested by Scheffé's multiple contrasts.
Results
Effects of EVOO phenolic compounds on breast cancer cell 
viability, proliferation, and apoptosis in HER2-
overexpressing SKBR3 breast cancer cells
We initially assessed the metabolic status of HER2-overex-
pressing SKBR3 breast cancer cells following treatments
with graded micromolar concentrations of EVOO
polyphenols (6.25 → 100 μM). After 5 days of treatment,
cell viability was measured using a tetrazolium salt-based
(MTT) assay, and the IC50 value for each EVOO polyphe-
nol was calculated as described in "Materials and meth-
ods". EVOO single phenols failed to significantly decrease
SKBR3 cell viability. Thus, concentrations higher than 100
μM were needed to achieve cytotoxic responses in the
presence of hydroxytyrosol, tyrosol, and elenolic acid
(fractions 1, 2 and 3 respectively) (Figure 2). EVOO lign-
ans exhibited significant cytotoxic activities against SKBR3
cells. Fraction 6, which mainly contained 1-(+)-acetoxypi-
noresinol was more effective than fraction 5, which
mainly contained (+)-pinoresinol (IC50s = 51 ± 2 μM and
72 ± 5 μM, respectively) (Figure 2). Among the EVOO
phenolic fractions tested, those containing the secoiri-
doids DAOA, oleuropein aglycone, and ligstroside agly-
cone were the most potent at decreasing breast cancer cell
viability, with all of them exhibiting IC50 values lower
than 50 μM (e.g. as low as 26 ± 6 μM for the fraction 8
mainly containing the secoiridoid ligstroside aglycone)
(Figure 2). Equivalent pictures emerged when the dose-BMC Cancer 2008, 8:377 http://www.biomedcentral.com/1471-2407/8/377
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response effects of EVOO polyphenols on the prolifera-
tion rate of SKBR3 were assessed by photometry after crys-
tal violet staining. As shown in Figure 3 (left panel), EVOO
single phenols and polyphenol acids produced weak
growth inhibitory effects in SKBR3 cells. By contrast, the
fractions 5 and 6 containing EVOO lignans (Figure 3, mid-
dle panel) and the fractions 4, 7 and 8 containing EVOO
secoiridoids (Figure 3, right panel) significantly inhibited
SKBR3 cell proliferation in a concentration-dependent
manner.
To evaluate whether the inhibitory effects of EVOO-
derived lignans and secoiridoids on breast cancer cell via-
bility and proliferation might actually be due to changes
in apoptotic cell death, SKBR3 cells were exposed to
increasing concentrations of EVOO phenolics, apoptotic
cell death was measured by a Cell Death ELISA detecting
apoptosis-induced DNA-histone fragmentation, and the
x-fold increase in apoptosis was calculated by comparing
the ELISA optical density readings of treated samples
(with the values obtained in untreated cells as 1.0). In
agreement with the results obtained in cell viability and
cell proliferation assays, the lowest degree of apoptotic
cell death was achieved upon treatment with hydroxytyro-
sol and elenolic acid (Figure 4). Treatment with the lign-
ans-rich fractions 5 and 6 notably increased (up to ~10-
fold at 100 μM 1-(+)-acetoxypinoresinol) the apoptotic
cell death of SKBR3 cells (Figure 4). SKBR3 cells were like-
Effects of EVOO phenolics on breast cancer cell proliferation Figure 3
Effects of EVOO phenolics on breast cancer cell proliferation. SKBR3 cells were incubated with various concentra-
tions of EVOO single phenols (left), fractions containing mainly EVOO lignans (middle) and fractions containing mainly EVOO 
secoiridoids (right) for 4 days. Cell proliferation, measured using a crystal violet assay as described in "Materials and methods", 
was expressed as % of untreated cells (dashed line = 100% cell proliferation). Results are means (columns) and 95% confidence 
intervals (bars) of three independent experiments made in triplicate. Statistically significant differences (one-factor ANOVA 
analysis) between experimental conditions and unsupplemented control cells are shown. All statistical tests were two-sided.BMC Cancer 2008, 8:377 http://www.biomedcentral.com/1471-2407/8/377
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Effects of EVOO phenolics on breast cancer apoptotic cell death Figure 4
Effects of EVOO phenolics on breast cancer apoptotic cell death. Quantification of apoptosis-related cell death in 
SKBR3 cells treated with increasing concentrations of EVOO phenolics was determined by Cell Death ELISA as described in 
"Materials and methods". The enrichment of histone-DNA fragments EVOO polyphenols-treated cells was expressed as fold-
increase in absorbance by comparing with control (vehicle-treated) cells using the following formula: [A405 – A490]TREATED/[A405-
A490]UNTREATED. Data are the mean (columns) and 95% confidence intervals (bars) of three independent experiments performed 
in duplicate. One-factor ANOVA was used to analyze differences in the percentage of apoptosis between the various treat-
ment groups and the control group. Statistically significant differences (one-factor ANOVA analysis) between experimental 
conditions and unsupplemented control cells are shown (one-factor analysis of variance). All statistical tests were two-sided. 
N.S.: Not statistically significant.BMC Cancer 2008, 8:377 http://www.biomedcentral.com/1471-2407/8/377
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wise exquisitely sensitive to secoiridoids-rich fractions 4,
7 and 8 as they exhibited the highest degree of apoptotic
cell death following exposure to fraction 4 (DAOA, > 5-
fold increase), fraction 8 containing (ligstroside aglycone,
> 25-fold increase), and fraction 7 (oleuropein aglycone,
> 10-fold increase) (Figure 4). Interestingly, the precursor
form oleuropein glycoside was significantly less effective
than its oleuropein aglycone derivative, thus revealing
that the glucose moiety in oleuropein structure strongly
affects its anti-breast cancer activity (Figure 4).
EVOO phenolics preferentially inhibit the proliferation of 
HER2-overexpressing breast cancer cells
SKBR3 cells represent a widely used breast cancer in vitro
model characterized by exhibiting natural HER2  gene
amplification, HER2 receptor protein overexpression and
HER2-dependency for cell proliferation and survival
[38,39]. To evaluate whether EVOO polyphenols prefer-
entially exhibit tumoricidal effects against HER2-overex-
pressing breast cancer cells, we further explored both the
apoptotic/anti-proliferative effects of EVOO polyphenols
in MCF-7 breast cancer cells – which express physiological
levels of HER2 (i.e. one single copy of HER2 gene) and in
MCF-7 cells stably transduced with pBABE-HER2 or
pBABE (empty control) retroviral vectors. The level of
HER2 overexpression achieved in MCF-7/(pBABE)HER2
cells (~70-fold increase when compared to MCF-7/pBABE
matched control and MCF-7 parental cells) was compara-
ble to that reported in MCF-7/Her2-18 cells, a well-char-
acterized MCF-7-derived HER2-overexpressing clone
engineered to stably express the full-length human HER2
cDNA controlled by a SV40 viral promoter [40]. Forced
expression of HER2 in MCF-7 cells increased by > 4-fold
the apoptotic effects of the fraction 6 containing the
EVOO lignan 1-(+)-acetoxypinoresinol. High levels of
HER2 promoted also exacerbated apoptotic responses to
fractions 4, 7 and 8 containing mainly EVOO secoiridoids
DAOA, ligstroside aglycone, and oleuropein aglycone,
respectively. For example, treatment with the DAOA-rich
fraction 4 increased apoptotic cell death by 17.5-times
and 7.1-times in HER2-overexpressing MCF-7/HER2
transfectants and in HER2-negative MCF-7/pBABE
matched control cells, respectively (Figure 5). The notion
that HER2 overexpression in breast cancer cells signifi-
cantly decreases the capability of human breast epithelial
cells to overcome EVOO polyphenols-induced cell inju-
ries was further supported when analyzing the anti-prolif-
erative effects of EVOO polyphenols in MCF-7/pBABE
and MCF-7/HER2 cells. As shown in Figure 6 (left panel),
EVOO single phenols and EVOO polyphenol acids were
ineffective against HER2-negative MCF-7/pBABE cells
while they exhibited weak growth-inhibitory effects
against HER2-overexpressing MCF-7/HER2 cells. Remark-
ably, the fraction 6 containing mainly the EVOO lignan 1-
(+)-acetoxypinoresinol reduced the proliferation rate of
MCF-7/HER2 cells by 63%, whereas this reduction was as
low as 26% in MCF-7/pBABE matched control cells (Fig-
ure 6, middle panel). All the EVOO secoiridoids exhibited
slight anti-proliferative effects in HER2-negative MCF-7/
pBABE cells. Conversely, HER2-overexpressing MCF-7/
HER2 cells were exquisitely sensitive to the growth-inhib-
itory effects of DAOA-rich fraction 4 (~80% inhibition of
cell proliferation at 100 μM), ligstroside aglycone-rich
fraction 8 (~50% inhibition of cell proliferation at 100
μM) and oleuropein aglycone-rich fraction 7 (~55% inhi-
bition of cell proliferation at 100 μM) (Figure 6, right
panel). Overall, these results suggest that EVOO polyphe-
nols preferentially suppress the growth of HER2-overex-
pressing breast cancer cells.
EVOO polyphenols deplete HER2 oncoprotein
To evaluate whether, in terms of cell viability, the biolog-
ical activity of EVOO polyphenols did require HER2 over-
expression as a necessary molecular "hallmark", we used a
siRNA HER2 depletion approach to determine the effect
of "HER2 protein-dose" on the sensitivity of breast cancer
cells to EVOO polyphenols. SKBR3 and MCF-7/HER2
cells were transfected with 80 pmols of HER2 siRNA or
control siRNA (i.e. siRNA A). 72 h after HER2-targeted
siRNA transfection, HER2 protein levels decreased up to
~65-70% of those present in SKBR3 and MCF-7/HER2
cells transfected with a control siRNA (Figure 1, Addi-
tional file 1). Interestingly, a combination of sequential
HER2 siRNA followed by treatment with sub-optimal
doses of the 1-[+]-acetoxypinoresinol-rich fraction 6 and
of the DAOA-rich fraction 4 strikingly demonstrated an
antagonistic to protective nature of the cytotoxic interac-
tion (Interaction Indexes > 2.0; Figure 7).
The fact that depletion of endogenous HER2 significantly
prevented the growth-inhibitory effects of EVOO
polyphenols together with our earlier findings demon-
strating that the down-regulatory effects of the secoiridoid
oleuropein aglycone were specifically restricted to HER2
without affecting other key members of the oncogenic
HER network such as HER1 (EGFR) [20], suggested that
secoiridoids- and lignans-induced changes in cell viability
might relate, at least in part, to changes in the expression
of HER2 oncoprotein. To evaluate this hypothesis we
examined the effects of long-term treatments (i.e.  48
hours) with graded concentrations of EVOO polyphenols
on the naturally-occurring overexpression of HER2 pro-
tein in SKBR3 cells (Figure 8). At its highest concentration
(i.e. 100 μM), the EVOO single phenol hydroxytyrosol
slightly reduced HER2 protein expression by 35%.
Remarkably, HER2 expression was drastically reduced by
68% and 86% in the presence of 100 μM of the fractions
5 and 6 containing mainly EVOO lignans (+)-pinoresinol
and 1-(+)-acetoxypinoresinol, respectively. Similarly to
EVOO lignans, EVOO secoiridoids were very effective atBMC Cancer 2008, 8:377 http://www.biomedcentral.com/1471-2407/8/377
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inhibiting HER2 expression, with inhibitory percentages
ranging from 50%–60% in the presence of DAOA-rich
fraction 4 and ligstroside aglycone-rich fraction 8 to 87%
inhibition upon treatment with the oleuropein aglycone-
rich fraction 7. We then evaluated if the growth inhibitory
effects of EVOO polyphenols against MCF-7/HER2 cells
were also accompanied with changes in the expression
levels of HER2 oncoprotein (Figure 9). The EVOO single
Apoptotic effects of EVOO phenolics in MCF-7 breast cancer cells engineered to overexpress HER2 Figure 5
Apoptotic effects of EVOO phenolics in MCF-7 breast cancer cells engineered to overexpress HER2. Quantifica-
tion of apoptosis-related cell death in MCF-7/HER2 and MCF-7/pBABE matched control cells treated with increasing concen-
trations of EVOO phenolics was determined by Cell Death ELISA as described in "Materials and methods". The enrichment of 
histone-DNA fragments in EVOO polyphenols-treated cells was expressed as fold-increase in absorbance by comparing with 
control (vehicle-treated) cells using the following formula: [A405 – A490]TREATED/[A405-A490]UNTREATED. Data are the mean (col-
umns) and 95% confidence intervals (bars) of three independent experiments performed in duplicate. One-factor ANOVA was 
used to analyze differences in the percentage of apoptosis between HER2-negative MCF-7/pBABE cells and HER2-positive 
MCF-7/HER2 cells. Statistically significant differences are shown (one-factor ANOVA analysis). All statistical tests were two-
sided.BMC Cancer 2008, 8:377 http://www.biomedcentral.com/1471-2407/8/377
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phenol hydroxytyrosol notably decreased HER2 protein
expression by 41%, while the fraction 6 containing
mainly the EVOO lignan 1-(+)-acetoxypinoresinol drasti-
cally reduced HER2 expression by 83%. All the EVOO
secoiridoids significantly reduced HER2 expression, from
~30% inhibition in the presence of DAOA-rich fraction 4
to 56% inhibition in the presence of the oleuropein agly-
cone-rich fraction 7. These findings reveal for the first time
that all the major complex phenols present in EVOO (i.e.
secoiridoids and lignans) drastically suppress HER2 onco-
protein overexpression in human breast cancer cells. Nei-
ther secoiridoids nor lignans treatments caused detectable
changes in HER1 (EGFR) expression in breast cancer cells
(data not shown).
EVOO polyphenols inhibit HER2 tyrosine phosphorylation
Since apigenin and luteolin, two naturally occurring fla-
vonoids structurally related to EVOO polyphenols, have
been found to inhibit tyrosine phosphorylation and
deplete HER2 protein through HER2 protein degradation
[41-43], we envisioned that an analogous posttransla-
tional mechanism may also contribute to the anti-HER2
actions of EVOO polyphenols. First, to evaluate whether
the biological activity of EVOO polyphenols in terms of
cell viability not only related to HER2 protein overexpres-
Effects of EVOO phenolics on HER2-enhanced breast cancer cell proliferation Figure 6
Effects of EVOO phenolics on HER2-enhanced breast cancer cell proliferation. MCF-7/HER2 cells and MCF-7/
pBABE matched control cells were incubated with 100 μM of EVOO single phenols (left), fractions containing mainly EVOO lig-
nans (middle) and fractions containing mainly EVOO secoiridoids (right) for 4 days. Cell proliferation, measured using a crystal 
violet assay as described in "Materials and methods", was expressed as % of untreated cells (dashed line = 100% cell prolifera-
tion). Results are means (columns) and 95% confidence intervals (bars) of three independent experiments made in triplicate. 
Statistically significant differences (one-factor ANOVA analysis) between HER2-negative MCF-7/pBABE control cells and 
HER2-positive MCF-7/HER2 cells are shown. All statistical tests were two-sided.BMC Cancer 2008, 8:377 http://www.biomedcentral.com/1471-2407/8/377
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sion but further required an enhanced tyrosine kinase
activity of HER2 as a molecular "hallmark" in EVOO
polyphenols-sensitive breast cancer cells, we used a phar-
macological approach to determine the effect of "HER2
activity-dose" on the tumoricidal effects of EVOO
polyphenols. Similarly to siRNA HER2-induced depletion
of HER2 protein, specific blockade of HER2 constitutive
hyperactivation (autophosphorylation at Tyr1248; Figure
2, Additional file 1) using the dual-HER1/HER2 tyrosine
kinase inhibitor lapatinib (Tykerb™) was sufficient to pre-
clude any further cytotoxic action of EVOO polyphenols.
Thus, a combination of sequential lapatinib (0.1 μM) fol-
lowed by treatment with sub-optimal doses of the 1-[+]-
acetoxypinoresinol-rich fraction 6 and DAOA-rich frac-
tion 4 demonstrated an antagonistic to protective nature
in their cytotoxic interactions (Interaction Indexes > 2.0;
Figure 10). To investigate the kinetics of inhibition/deple-
tion of HER2 activity/expression, we treated SKBR3 and
MCF-7/HER2 cells with EVOO polyphenols for different
time periods and harvested them for ELISA-based analysis
of HER2 protein expression. HER2 tyrosine autophospho-
rylation levels (i.e.  activation status of HER2 Tyr1248)
were measured by immunoblotting procedures. The
HER2 protein levels decreased in a time-dependent man-
ner following exposure to EVOO polyphenols, with sig-
nificant HER2 depleting effects occurring as early as 6 hr
after treatment with the fraction 6 containing mainly 1-
[+]-acetoxypinoresinol (Figure 11). Fraction 6-decreased
HER2 protein led to a coordinate decrease in HER2 auto-
phosphorylation, which significantly declined after 6 hr
and was barely detectable after 24 hr (Figure 11).
Although less markedly than fraction 6, the fraction 4 con-
taining mainly the EVOO secoiridoid DAOA also
decreased HER2 protein expression and HER2 tyrosine
kinase activity in a time-dependent manner, with the
most significant anti-HER2 expression/activity effects
occurring after 48 hr (Figure 11). These findings, alto-
gether, strongly suggest that EVOO polyphenols could
inhibit HER2 protein kinase activity by depleting the
HER2 protein kinase itself.
EVOO polyphenols-induced depletion of HER2 protein 
depends on proteasomal degradation but does not relate 
to anti-oxidant effects
The finding that all the major complex phenols present in
EVOO (i.e. lignans and secoiridoids) exhibit the ability to
drastically down-regulate HER2 protein regardless of the
molecular mechanism contributing to HER2 overexpres-
sion (i.e. naturally by gene amplification in SKBR3 cells
and ectopically driven by a viral promoter in MCF-7 cells
transduced with the human HER2 cDNA) suggested that
the anti-HER2 effects of EVOO polyphenols did not relate
Effects of HER2 siRNA on EVOO polyphenols-induced cytotoxicity Figure 7
Effects of HER2 siRNA on EVOO polyphenols-induced cytotoxicity. ~5 × 103 cells (96-well plates) overnight serum-
starved SKBR3 (left) and MCF-7/HER2 (right) cells were transfected with HER2 siRNA or control siRNA (80 pmols/well) 
before exposure to 25 μM 1-[+]-acetoxypinoresinol or 25 μM DAOA. The metabolic status of SKBR3 and MCF-7/HER2 cells 
was evaluated using a MTT-based cell viability assay and Interaction Indexes were calculated by dividing expected cytotoxicities 
(additive models: sum of cell toxicities induced by each agent alone) by those obtained experimentally in the actual combination 
(Interaction Indexes < 1, = 1, > 1 < 2, and > 2 denote a nature of the interaction synergistic, additive, antagonistic and protec-
tive, respectively). Results are means (dots) and 95% confidence intervals (bars) of three independent experiments made in trip-
licate.BMC Cancer 2008, 8:377 http://www.biomedcentral.com/1471-2407/8/377
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to factors controlling the rate of HER2 gene promoter-reg-
ulated HER2 de novo synthesis [44,45]. Accordingly, HER2
mRNA levels did not significantly decline even after 24
hours after treatment with EVOO polyphenols (data not
shown). To better delineate the mechanism of EVOO
polyphenols-mediated HER2 down-regulation, we tested
the following hypotheses: 1.) Since all the main polyphe-
nols that occur at high levels in EVOO have demonstrated
antioxidant activity and antioxidants are believed to be
responsible for a number of EVOO's biological activities,
we envisioned that EVOO polyphenols-induced deple-
tion of HER2 might represent a general response of HER2-
overexpressing cancer cells growing upon anti-oxidant
conditions. To test this hypothesis MCF-7/HER2 cells and
MCF-7/pBABE matched control cells were treated with
graded concentrations of the well-established anti-oxi-
dants 6-hydroxy-N-acetylcysteine (NAC, a glutathione
precursor and scavenger of reactive oxygen species) and
2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox, a
water-soluble vitamin E analogue). Interestingly, MCF-7/
HER2 cells were more sensitive to the anti-proliferative
effects of NAC (Figure 3; Additional file 1) and Trolox
Influence of EVOO phenolics on the levels of HER2 oncoprotein in SKBR3 breast cancer cells Figure 8
Influence of EVOO phenolics on the levels of HER2 oncoprotein in SKBR3 breast cancer cells. Overnight serum-
starved SKBR3 cells were cultured in DMEM medium-0.1% FBS in the absence or presence of increasing concentrations of 
EVOO phenolics for 48 h. The Oncogene Science HER2 microtiter ELISA was used according to the manufacturer's instruc-
tions to compare HER2 protein concentrations in whole cell lysates from EVOO polyphenols-treated and untreated control 
cells. Results are means (columns) and 95% confidence intervals (bars) of three independent experiments made in triplicate. Sta-
tistically significant differences between experimental conditions and unsupplemented control cells are shown (one-factor 
ANOVA analysis). All statistical tests were two-sided.BMC Cancer 2008, 8:377 http://www.biomedcentral.com/1471-2407/8/377
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(Figure 4; Additional file 1) as they exhibited IC50 values
significantly lower (3 to 4-times) than those found in
MCF-7/pBABE cells. However, treatment with either
Trolox or NAC failed to modulate HER2 protein levels in
MCF-7/HER2 cells (Figures 3 and 4; Additional file 1).
Overall, these results suggest that anti-oxidant agents pref-
erentially suppress the growth of HER2-overexpressing
cancer cells, whereas promoting an antioxidant status in
HER2-positive breast cancer cells is not sufficient to
down-regulate HER2 expression in human breast cancer
cells.
Since the ability of EVOO polyphenols to deplete HER2
protein did not appear to relate to their impact on the
antioxidant status of breast cancer cells, we then specu-
lated that EVOO secoiridoids and lignans might deplete
Influence of EVOO phenolics on the levels of HER2 oncoprotein in MCF-7/HER2 breast cancer cells Figure 9
Influence of EVOO phenolics on the levels of HER2 oncoprotein in MCF-7/HER2 breast cancer cells. Overnight 
serum-starved MCF-7/HER2 cells were cultured in DMEM medium-0.1% FBS in the absence or presence of increasing concen-
trations of EVOO phenolics for 48 h. The Oncogene Science HER2 microtiter ELISA was used according to the manufacturer's 
instructions to compare HER2 protein concentrations in whole cell lysates from EVOO polyphenols-treated and untreated 
control cells. Results are means (columns) and 95% confidence intervals (bars) of three independent experiments made in tripli-
cate. Statistically significant differences between experimental conditions and unsupplemented control cells are shown (one-
factor ANOVA analysis). All statistical tests were two-sided.BMC Cancer 2008, 8:377 http://www.biomedcentral.com/1471-2407/8/377
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HER2 through proteolysis, the molecular mechanism
through which other structurally related plant polyphe-
nols such as the flavonoids apigenin and luteolin suppress
HER2 protein expression in breast cancer cells [41-43]. A
role of proteasomal degradation in EVOO polyphenols-
mediated HER2 down-regulation was likewise supported
by the fact that pre-treatment (2 hr) with the proteasome
inhibitor MG-132 fully prevented the reduction of HER2
protein levels induced by EVOO polyphenols (Figure 12).
To further corroborate the suggestion that EVOO
polyphenols induce cell growth inhibition by depleting
HER2 protein in HER2-overexpressing breast cancer cells
via proteasomal degradation, we analyzed whether supra-
additive or synergistic interactions occurred upon concur-
rent treatment with EVOO polyphenols and anti-HER2
agents that promote HER2 down-regulation through pro-
teasome-independent mechanisms [12,46,47]. Simulta-
neous exposure of SKBR3 cells to the anti-HER2
monoclonal antibody trastuzumab with sub-optimal
doses of the 1-(+)-acetoxypinoresinol-rich fraction 6 or
the DAOA-rich fraction 4 likewise demonstrated greater
decreases in cell viability that did each agent alone (Inter-
action Indexes < 1.0; Figure 13). This synergistic interac-
tion occurring between EVOO-derived lignans and
secoiridoids further extends our previous findings that
demonstrated a supra-additive cytotoxic effect when com-
bining trastuzumab with the EVOO secoiridoid oleuro-
pein aglycone [20].
Discussion
The ultimate molecular mechanism(s) determining how
specific components of EVOO may influence the genetic
program that drives breast cancer development and pro-
gression remain(s) largely obscure. Our experimental
approach in the last few years has suggested that EVOO-
related anti-breast cancer actions mainly affect the occur-
rence, the aggressive behavior and the therapeutic man-
agement of HER2  oncogene-driven breast carcinomas.
First, when we used one of the most useful in vivo carcino-
genesis systems of breast cancer – that of the DMBA-
induced mammary carcinogenesis in female Sprague-
Dawley rats, in which stepwise molecular analysis of the
transformation process is conducted from the very early to
the terminal stages of tumor development – a high EVOO
diet was found to act as a negative modulator of the mam-
mary carcinogenesis induced by genotoxic agents, confer-
Influence of the activation (phosphorylation) status of HER2 tyrosine kinase activity on the cytotoxic activity of EVOO  polyphenols Figure 10
Influence of the activation (phosphorylation) status of HER2 tyrosine kinase activity on the cytotoxic activity of 
EVOO polyphenols. ~5 × 103 cells (96-well plates) overnight serum-starved SKBR3 (left) and MCF-7/HER2 (right) cells were 
treated with 0.1 μM lapatinib before exposure to 25 μM 1-[+]-acetoxypinoresinol or 25 μM DAOA. The metabolic status of 
treated and untreated control cells was evaluated using a MTT-based cell viability assay and Interaction Indexes were calculated 
by dividing expected cytotoxicities (additive models: sum of cell toxicities induced by each agent alone) by those obtained 
experimentally in the actual combination (Interaction Indexes < 1, = 1, > 1 < 2, and > 2 denote a nature of the interaction syn-
ergistic, additive, antagonistic and protective, respectively). Results are means (dots) and 95% confidence intervals (bars) of 
three independent experiments made in triplicate.BMC Cancer 2008, 8:377 http://www.biomedcentral.com/1471-2407/8/377
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ring to the tumors mainly an indolent clinical behavior
and a histopathological pattern compatible with a lower
degree of malignancy [13,14]. Mechanistically, we dem-
onstrated that high EVOO diet influenced negatively
experimental mammary carcinogenesis modifying the
mRNA expression levels of neu  (HER2) [14]. Second,
when using human breast cancer-derived in vitro models
naturally exhibiting HER2 gene amplification and HER2
protein overexpression, exogenous supplementation with
physiological concentrations of oleic acid (OA; 18:1n-9) –
the main ω-9 monounsaturated fatty acid (MUFA) in
EVOO – was found to drastically suppress the expression
of HER2 and to synergistically enhance both the growth-
inhibitory and the HER2 down-regulatory effects of the
monoclonal antibody trastuzumab (Herceptin™) [15-17].
The above findings generated intense public interest, since
no toxicities have been reported or suspected with OA,
and suggested that supplementation with EVOO might
represent a promising dietary intervention aimed to pre-
vent and/or manage HER2-related carcinomas. However,
it should be noted that EVOO consists primarily of tria-
cylglycerols rich in the ω-9 MUFA OA and non-glyceridic
Influence of EVOO polyphenols on the levels of HER2 tyrosine kinase activity Figure 11
Influence of EVOO polyphenols on the levels of HER2 tyrosine kinase activity. Overnight serum-starved SKBR3 
(left) and MCF-7/HER2 (right) cells were treated with 100 μM 1-[+]-acetoxypinoresinol and 100 μM DAOA for 0, 6, 24 and 48 
hr. Oncogene Science HER2 microtiter ELISA was used according to the manufacturer's instructions to compare HER2 protein 
concentrations in whole cell lysates throughout the time-course. HER2 expression at the 0 hr-time point was set as 100%. 
Results are means (columns) and 95% confidence intervals (bars) of three independent experiments made in triplicate. Statisti-
cally significant differences between experimental conditions and unsupplemented control cells at the 0 hr-time point are 
shown (one-factor ANOVA analysis). All statistical tests were two-sided. EVOO polyphenols-treated and untreated control 
cells (0 hr) were tested in parallel for p185HER2 autophosphorylation at Tyr1248 using immunoblotting procedures as described 
in "Materials and methods".BMC Cancer 2008, 8:377 http://www.biomedcentral.com/1471-2407/8/377
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constitutes comprising approximately 0.5% to 1% EVOO,
which include at least 30 phenolic compounds. Although
we recently presented evidence that the aglycone form of
oleuropein – a member of the secoiridoid family of EVOO
polyphenols that has mainly been implicated in the orga-
noleptic characteristics of EVOO such as bitterness – sig-
nificantly enhances the efficacy of anti-HER2 therapeutics
in cultured HER2-overexpressing breast cancer cells when
compared to simple phenols (e.g. tyrosol, hydroxytyro-
sol) [20], the anti-breast cancer effects of other EVOO-
derived polyphenols such as the lignan (+)-1-acetoxypi-
noresinol or the secoiridoids deacetoxy oleuropein agly-
cone and ligstroside aglycone remained to be addressed.
We now provide new insights on the mechanisms by
which good-quality OO, i.e.  polyphenols rich-EVOO,
may contribute to lower breast cancer risk in a HER2-
dependent manner. First, EVOO phenolic compounds
with a simple structure, involving only a single phenol
ring might be incapable to exert strong anti-breast cancer
actions. Indeed, a more complex (i.e. polyphenolic) struc-
ture appears to be required in order to exert these effects.
Thus, both the EVOO-derived single phenols tyrosol and
Effects of proteasome inhibition on EVOO polyphenols-induced down-regulation of HER2 protein in breast cancer cells Figure 12
Effects of proteasome inhibition on EVOO polyphenols-induced down-regulation of HER2 protein in breast 
cancer cells. MCF-7/HER2 cells were exposed to three different schedules: 1.) 1 μM MG-132 (2 hr) → EVOO polyphenols 
(up to 48 hr); 2.) DMSO (v/v; 2 hr) → EVOO polyphenols (up to 48 hr); 3.) 1 μM MG-132 (2 hr) → EtOH (v/v; up to 48 hr). 
Oncogene Science HER2 microtiter ELISA was used according to the manufacturer's instructions to compare HER2 protein 
concentrations in whole cell lysates from schedules #1, #2, and #3. HER2 expression in untreated control cells was set as 
100%. Results are means (columns) and 95% confidence intervals (bars) of three independent experiments made in triplicate. 
Statistically significant differences between experimental conditions and unsupplemented control cells are shown (one-factor 
ANOVA analysis).BMC Cancer 2008, 8:377 http://www.biomedcentral.com/1471-2407/8/377
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hydroxytyrosol and the EVOO-derived polyphenol acid
elenolic acid exhibited significantly lower anti-prolifera-
tive and pro-apoptotic effects than those observed with
the EVOO fractions rich in the complex polyphenols lign-
ans and secoiridoids. Second, when we investigated the
tumoricidal effects of EVOO polyphenols against breast
epithelial cells bearing different endogenous levels of the
HER2 oncogene, it became clear that high levels of HER2
oncoprotein constitute a molecular feature through which
EVOO polyphenols exert, at least in part, their anti-breast
Synergy analysis of the concurrent combination with EVOO polyphenols and the anti-HER2 monoclonal antibody trastuzumab  in SKBR3 breast cancer cells Figure 13
Synergy analysis of the concurrent combination with EVOO polyphenols and the anti-HER2 monoclonal anti-
body trastuzumab in SKBR3 breast cancer cells. ~5 × 103 cells (96-well plates) overnight serum-starved SKBR3 cells 
were treated with 100 μg/ml trastuzumab in the absence or presence of 25 μM 1-[+]-acetoxypinoresinol or 25 μM DAOA. 
The metabolic status of treated and untreated control cells was evaluated using a MTT-based cell viability assay and Interaction 
Indexes were calculated by dividing expected cytotoxicities (additive models: sum of cell toxicities induced by each agent alone) 
by those obtained experimentally in the actual combination (Interaction Indexes < 1, = 1, > 1 < 2, and > 2 denote a nature of 
the interaction synergistic, additive, antagonistic and protective, respectively). Results are means (dots) and 95% confidence 
intervals (bars) of three independent experiments made in triplicate.BMC Cancer 2008, 8:377 http://www.biomedcentral.com/1471-2407/8/377
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cancer actions. EVOO polyphenols differentially induced
breast cancer cell growth inhibition by promoting apop-
totic cell death in HER2-positive breast cancer cells, with
marginal tumoricidal effects occurring in HER2-negative
breast cancer cells. Moreover, we found that EVOO
polyphenols repressed the phosphor-Tyrosine levels of
HER2 and also depleted HER2 protein levels. The definite
mode of action underlying EVOO polyphenols-induced
blockade of HER2 tyrosine kinase activity and down-reg-
ulation of HER2 protein expression was beyond the scope
of this study. Nevertheless, when considering that the pri-
mary mechanism driving HER2 levels in human breast
cancer cells is gene amplification and overexpression
under the control of the endogenous promoter [44,45],
the fact that EVOO polyphenols drastically decreased
HER2 protein content regardless the molecular mecha-
nism contributing to HER2 overexpression strongly sug-
gests that EVOO polyphenols do not significantly affect
the cellular transcriptional machinery that controls the
endogenous HER2 locus in breast cancer cells. Mechanis-
tically, and unlike the EVOO ω-9 MUFA OA – which has
been found to indirectly suppress the transcriptional activ-
ity of HER2  gene by up-regulating the transcriptional
repressor PEA3 and inducing formation of inhibitory
"PEA3 transcription factor-PEA3 DNA binding site" com-
plexes at the HER2 promoter – [18,19] the anti-HER2
effects of EVOO polyphenols appear to relate to the inhi-
bition of HER2 tyrosine kinase activity as a result of HER2
protein depletion. This notion is supported by the follow-
ing findings: 1.) EVOO polyphenols-induced inhibition
of HER2 expression does not reflect a wider and unspecific
inhibitory effect against other HER members closely
related to HER2 in terms of structure and activity [20]; 2.)
siRNA-induced depletion of HER2 protein protects breast
cancer cells against EVOO-induced cell growth inhibition,
thus suggesting that EVOO polyphenols should interact
necessarily with the HER2 protein itself to trigger their
mechanism of action; 3.) blocking ATP from binding to
the tyrosine kinase (TK) domain of HER2 upon treatment
with a potent, reversible, selective dual-HER1/HER2 TK
inhibitor lapatinib prevents EVOO polyphenols-induced
inhibition of breast cancer cell growth, thus suggesting
that EVOO lignans and secoiridoids may function as
phosphotyrosine-receptor kinase blockers by competing
with ATP; and 4.) pre-treatment of HER2-overexpressing
breast cancer cells with the proteasome inhibitor MG-132
blocks the depletion of HER2 protein induced by EVOO
polyphenols, thus suggesting that EVOO-derived lignans
and secoiridoids can efficiently inhibit HER2 protein
kinase activity by depleting the HER2 protein kinase itself.
Therefore, it is reasonable to suggest that EVOO polyphe-
nols directly affect HER2 levels by promoting proteasomal
degradation of HER2 as recently described for other struc-
turally-related naturally-occurring polyphenols such as
the flavonoids apigenin and luteolin [41-43].
Although our current findings provide new insights on the
mechanisms by which good-quality OO, i.e. polyphenols
rich-EVOO, might contribute to lower breast cancer risk in
a HER2-dependent manner, extreme caution must be
applied when extrapolating in vitro results into clinical
practice. One obvious limitation of our current results is
that the phenolics that were active (i.e. lignans and secoir-
idoids) exhibited tumoricidal effects against cultured
breast cancer cells at concentrations (> 50 μM) that are
unlikely to be achieved in vivo [46-48]. Indeed, it has to be
clarified if these compounds will be accessible in the
breast tumor tissue in vivo. In this regard, an important
step in the body metabolism might be that EVOO
polyphenols rapidly split into inactive compounds. In
this regard, the secoiridoid oleuropein aglycone is split
into hydroxytyrosol or tyrosol and elenolic acid [46-50],
both of them notably less effective than the parental
secoiridoid in terms of cytotoxicity and HER2 down-regu-
lation. Nevertheless, EVOO-derived lignans may represent
a different molecular scenario when compared to EVOO-
derived secoiridoids. Saarinen et al. recently evaluated the
accessibility and accumulation of lignans to breast cancer
tissue after their oral administration to athymic mice bear-
ing MCF-7 human breast cancer tumors [51]. Importantly,
tumor tissue accumulated up to 92% of the lignans levels
found in serum, thus suggesting that the anticancer activ-
ity of lignans may be due to their direct local effects on the
breast cancer tissues. Of note, a randomized double-blind
placebo-controlled clinical trial recently evaluated the
effects of dietary flaxseed, which has an exceptionally high
concentration of lignans on tumor biological markers in
postmenopausal patients with newly diagnosed breast
cancer [52]. The results of this clinical trial demonstrated
that daily intake of 25 g flaxseed can significantly reduce
cell proliferation, increase apoptosis, and affect cell sign-
aling by reducing HER2 expression of breast tumors. A
71.0% reduction in HER2 expression and an increase in
apoptosis (30.7%) were observed in the flaxseed, but not
in the placebo group. In fact, the total intake of flaxseed
correlated with changes in HER2 expression and apop-
totic index [52].
Conclusion
This study reveals for the first time that all the major fam-
ilies of EVOO polyphenols (i.e. secoiridoids and lignans)
represent previously unrecognized phytochemicals that
significantly affect breast cancer cell proliferation and sur-
vival through a molecular mechanism involving, at least
in part, a significant down-regulation of HER2 expression
and activity (Figure 14). These findings, together with the
fact that that humans have safely been ingesting signifi-
cant amounts of lignans and secoiridoids as long as they
have been consuming olives and EVOO, strongly suggest
that the stereochemistry of these polyphenols might pro-
vide an excellent and safe platform for the design of newBMC Cancer 2008, 8:377 http://www.biomedcentral.com/1471-2407/8/377
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anti-breast cancer drugs. Although EVOO-rich has been
linked with reduced breast cancer risk, and experimental
studies begin to support the hypothesis of EVOO pheno-
lics as inhibiting compounds of HER2-related breast can-
cer growth, important issues such as the accessibility of
EVOO-derived secoiridoids and lignans to tumor tissues
should be carefully addressed in animal models and
human pilot studies. Only then an appropriate dietary
intervention aimed to reproduce the prominent anti-
oncogenic features of EVOO phytochemicals could be
viewed as a new molecular approach in the management
of HER2-positive breast cancer disease.
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